203 related articles for article (PubMed ID: 8528167)
1. Allogeneic bone marrow transplantation following a busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: a Cooperative Study of the Société Française de Greffe de Moelle.
von Bueltzingsloewen A; Esperou-Bourdeau H; Souillet G; Demeocq F; Mechinaud-Lacroix F; Michel G; Sadoun A; Bernaudin F; Cornu G; Donadieu J
Bone Marrow Transplant; 1995 Oct; 16(4):521-7. PubMed ID: 8528167
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission: factors predictive of survival, relapse and graft-versus-host disease.
Moussalem M; Esperou Bourdeau H; Devergie A; Baruchel A; Ribaud P; Socie G; Parquet N; Traineau R; Hirsch I; Schaison G
Bone Marrow Transplant; 1995 Jun; 15(6):943-7. PubMed ID: 7581095
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen.
Matsuyama T; Kojima S; Kato K
Bone Marrow Transplant; 1998 Jul; 22(1):21-6. PubMed ID: 9678791
[TBL] [Abstract][Full Text] [Related]
4. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia conditioned with busulfan, cyclophosphamide and melphalan.
Carpenter PA; Marshall GM; Giri N; Vowels MR; Russell SJ
Bone Marrow Transplant; 1996 Sep; 18(3):489-94. PubMed ID: 8879607
[TBL] [Abstract][Full Text] [Related]
6. [Allogenic bone marrow transplantation versus autograft in acute lymphoblastic leukemia, in second remission in 113 children. Results of the Grupo Español de Transplante de Medula Niños (GETMON)].
Badell I; Ortega JJ; Muñoz A; Bureo E; Madero L; Olivé T; Cubells J; Maldonado MS; Baro J; Díaz MA
Sangre (Barc); 1996 Apr; 41(2):101-8. PubMed ID: 9045349
[TBL] [Abstract][Full Text] [Related]
7. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
8. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
9. Can busulfan replace fractionated total body irradiation as conditioning regimen for allogeneic bone marrow transplantation in children with acute lymphoblastic leukemia.
Wachowiak J; Bettoni C; Lange A; Malicki J; Kaczmarek-Kanold M; Głuszak B; Suchnicki K; Daszkiewicz P; Ebell W
Acta Haematol Pol; 1995; 26(4):377-84. PubMed ID: 8571739
[TBL] [Abstract][Full Text] [Related]
10. Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.
Kato K; Yoshida N; Matsumoto K; Matsuyama T
Pediatr Blood Cancer; 2014 Apr; 61(4):712-6. PubMed ID: 24376191
[TBL] [Abstract][Full Text] [Related]
11. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
Zander AR; Berger C; Kröger N; Stockshläder M; Krüger W; Horstmann M; Grimm J; Zeller W; Kabisch H; Erttmann R; Schönrock P; Kuse R; Braumann D; Illiger HJ; Fiedler W; de Witt M; Hossfeld KD; Weh HJ
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2671-5. PubMed ID: 10068272
[TBL] [Abstract][Full Text] [Related]
12. Treatment of infant leukemia with busulfan, cyclophosphamide +/- etoposide and bone marrow transplantation.
Emminger W; Emminger-Schmidmeier W; Haas OA; Urban C; Ambros P; Peters C; Mann G; Fink FM; Ferstl G; Höcker P
Bone Marrow Transplant; 1992 May; 9(5):313-8. PubMed ID: 1617314
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2).
Copelan EA; Biggs JC; Szer J; Thompson JM; Crilley P; Brodsky I; Klein JL; Kapoor N; Harman GS; Avalos BR
Semin Oncol; 1993 Aug; 20(4 Suppl 4):33-8; quiz 39. PubMed ID: 8342074
[TBL] [Abstract][Full Text] [Related]
14. Total body irradiation-high-dose cytosine arabinoside and melphalan followed by allogeneic bone marrow transplantation from HLA-identical siblings in the treatment of children with acute lymphoblastic leukaemia after relapse while receiving chemotherapy: a Société Française de Greffe de Moelle study.
Bordigoni P; Esperou H; Souillet G; Pico J; Michel G; Lacour B; Reiffers J; Sadoun A; Rohrlich P; Jouet JP; Milpied N; Lutz P; Plouvier E; Cornu G; Vannier JP; Gandemer V; Rubie H; Gratecos N; Leverger G; Stephan JL; Boutard P; Vernant JP
Br J Haematol; 1998 Aug; 102(3):656-65. PubMed ID: 9722290
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy.
Ortega JJ; Díaz de Heredia C; Olivé T; Bastida P; Llort A; Armadans L; Torrabadella M; Massuet L
Haematologica; 2003 Mar; 88(3):290-9. PubMed ID: 12651268
[TBL] [Abstract][Full Text] [Related]
16. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
Long GD; Amylon MD; Stockerl-Goldstein KE; Negrin RS; Chao NJ; Hu WW; Nademanee AP; Snyder DS; Hoppe RT; Vora N; Wong R; Niland J; Reichardt VL; Forman SJ; Blume KG
Biol Blood Marrow Transplant; 1997 Dec; 3(6):324-30. PubMed ID: 9502300
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic or autologous bone marrow transplantation for acute lymphoblastic leukemia in first complete remission.
Blaise D; Gaspard MH; Stoppa AM; Michel G; Gastaut JA; Lepeu G; Tubiana N; Blanc AP; Rossi JF; Novakovitch G
Bone Marrow Transplant; 1990 Jan; 5(1):7-12. PubMed ID: 2404531
[TBL] [Abstract][Full Text] [Related]
18. Isolated extramedullary relapse in children with acute lymphoblastic leukemia: a comparison between treatment results of chemotherapy and bone marrow transplantation. BFM Relapse Study Group.
Borgmann A; Hartmann R; Schmid H; Klingebiel T; Ebell W; Göbel U; Peters C; Gadner H; Henze G
Bone Marrow Transplant; 1995 Apr; 15(4):515-21. PubMed ID: 7655375
[TBL] [Abstract][Full Text] [Related]
19. Relapsed acute lymphoblastic leukemia: similar outcomes for autologous and allogeneic marrow transplantation in selected children.
Parsons SK; Castellino SM; Lehmann LE; Eickhoff CE; Tarbell NJ; Sallan SE; Weinstein HJ; Billett AL
Bone Marrow Transplant; 1996 May; 17(5):763-8. PubMed ID: 8733695
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of busulfan and melphalan as preparatory regimen prior to allogeneic bone marrow transplantation in refractory or relapsed hematological malignancies.
Vey N; De Prijck B; Faucher C; Stoppa AM; Sainty D; Lafage M; Bouabdallah R; Chabannon C; Camerlo J; Gastaut JA; Maraninchi D; Blaise D
Bone Marrow Transplant; 1996 Sep; 18(3):495-9. PubMed ID: 8879608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
